The purpose of this protocol is to pathologically evaluate the amount of destruction of cancer cells by Microwave Ablation (MWA) in primary breast tumors.
Minimally invasive surgical alternatives are becoming more attractive for the treatment of malignancy due to improvements in technology, reduced costs and reduced morbidity. The main objective of this protocol is to determine the extent of ablation based on time and power parameters of the MedWaves in breast cancers. This would be accomplished in patients diagnosed with breast cancer who are already scheduled for breast cancer surgery. Prior to the surgical removal of the cancer, the microwave antenna would be inserted into the tumor under ultrasound guidance (either percutaneously or open). The tumor would be ablated, and then surgically resected in a standard, curative fashion.
Study Type
OBSERVATIONAL
An 11-gauge microwave probe from MedWaves, Inc., will be placed in the tumor. An ablation lesion will then be generated at the appropriate power (10-35 watts) to maintain up to 130C degrees at the MW applicator tip thermocouple for 10 minutes duration. Palpation and/or ultrasound may be used to place the MWA needle and monitor the progress of the microwave ablation.
St. Joseph Hospital of Orange
Orange, California, United States
Amount of tissue destruction with MedWaves Microwave Ablation/ Coagulation System.
Measure tissue destruction with the MedWaves Microwave Ablation/ Coagulation System through pathological review of destruction.
Time frame: 30 days
Provide the differences between percutaneous and open Microwave Ablation
Evaluate differences between percutaneous and open Microwave Ablation through pathological review and patient follow-up.
Time frame: 30 Days
Amount of toxicity of microwave ablation in patients.
Measure toxicity of Microwave Ablation through patient follow-up and assessment.
Time frame: 30 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.